This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ayton, P. M. Articles by Cleary, M. L. Search for Related Content PubMed PubMed Citation Articles by Ayton, P. M. Articles by Cleary, M. L.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, December 2004, p. 10470-10478, Vol. 24, No. 23
0270-7306/04/$08.00+0     DOI: 10.1128/MCB.24.23.10470-10478.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Binding to Nonmethylated CpG DNA Is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein

Paul M. Ayton, Everett H. Chen, and Michael L. Cleary^*

Department of Pathology, Stanford University School of Medicine, Stanford, California

Received 14 August 2004/ Accepted 9 September 2004

The MLL gene is a frequent target for leukemia-associated chromosomal translocations that generate dominant-acting chimeric oncoproteins. These invariably contain the amino-terminal 1,400 residues of MLL fused with one of a variety of over 30 distinct nuclear or cytoplasmic partner proteins. Despite the consistent inclusion of the MLL amino-terminal region in leukemia oncoproteins, little is known regarding its molecular contributions to MLL-dependent oncogenesis. Using high-resolution mutagenesis, we identified three MLL domains that are essential for in vitro myeloid transformation via mechanisms that do not compromise subnuclear localization. These include the CXXC/Basic domain and two novel domains of unknown function. Point mutations in the CXXC domain that eliminate myeloid transformation by an MLL fusion protein also abolished recognition and binding of nonmethylated CpG DNA sites in vitro and transactivation in vivo. Our results define a critical role for the CXXC DNA binding domain in MLL-associated oncogenesis, most likely via epigenetic recognition of CpG DNA sites within the regulatory elements of target genes.

P.M.A. and E.H.C. contributed equally to this study.

This article has been cited by other articles:

• Erfurth, F. E., Popovic, R., Grembecka, J., Cierpicki, T., Theisler, C., Xia, Z.-B., Stuart, T., Diaz, M. O., Bushweller, J. H., Zeleznik-Le, N. J. (2008). MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc. Natl. Acad. Sci. USA 105: 7517-7522 [Abstract] [Full Text]  
• Attema, J. L., Papathanasiou, P., Forsberg, E. C., Xu, J., Smale, S. T., Weissman, I. L. (2007). Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis. Proc. Natl. Acad. Sci. USA 104: 12371-12376 [Abstract] [Full Text]  
• Sanchez, C., Sanchez, I., Demmers, J. A. A., Rodriguez, P., Strouboulis, J., Vidal, M. (2007). Proteomics Analysis of Ring1B/Rnf2 Interactors Identifies a Novel Complex with the Fbxl10/Jhdm1B Histone Demethylase and the Bcl6 Interacting Corepressor. Mol. Cell. Proteomics 6: 820-834 [Abstract] [Full Text]  
• Lukasik, S. M., Cierpicki, T., Borloz, M., Grembecka, J., Everett, A., Bushweller, J. H. (2006). High resolution structure of the HDGF PWWP domain: A potential DNA binding domain. Protein Sci. 15: 314-323 [Abstract] [Full Text]  
• Sun, X.-J., Wei, J., Wu, X.-Y., Hu, M., Wang, L., Wang, H.-H., Zhang, Q.-H., Chen, S.-J., Huang, Q.-H., Chen, Z. (2005). Identification and Characterization of a Novel Human Histone H3 Lysine 36-specific Methyltransferase. J. Biol. Chem. 280: 35261-35271 [Abstract] [Full Text]  
• Di Croce, L. (2005). Chromatin modifying activity of leukaemia associated fusion proteins. Hum Mol Genet 14: R77-R84 [Abstract] [Full Text]